相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
Christos Vallilas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
Sebastian Bauer et al.
CLINICAL CANCER RESEARCH (2021)
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George et al.
EUROPEAN JOURNAL OF CANCER (2021)
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
John R. Zalcberg et al.
ONCOLOGIST (2021)
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
John Nemunaitis et al.
FUTURE ONCOLOGY (2020)
Impact of oral mucositis on quality of life in patients undergoing oncological treatment: a systematic review
Ali Hatem Manfi Al-Rudayni et al.
TRANSLATIONAL CANCER RESEARCH (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith et al.
CANCER CELL (2019)
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
Lena Fauske et al.
CLINICAL SARCOMA RESEARCH (2019)
Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors
Catherine Benedict et al.
PSYCHO-ONCOLOGY (2018)
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications
Zoltan Szucs et al.
FUTURE ONCOLOGY (2017)
Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients
Michelle Lui et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2017)
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
Peter Reichardt et al.
BMC CANCER (2016)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
Sunitinib: the antiangiogenic effects and beyond
Zhonglin Hao et al.
ONCOTARGETS AND THERAPY (2016)
Clinical Outcomes of Patients With Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-Use Trial of Sunitinib
Peter Reichardt et al.
CANCER (2015)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors
Jian Li et al.
FUTURE ONCOLOGY (2012)
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon et al.
INVESTIGATIONAL NEW DRUGS (2012)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastrointestinal stromal tumour
Brian P. Rubin et al.
LANCET (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
